Heartflow (NASDAQ:HTFL) Research Coverage Started at Weiss Ratings

Weiss Ratings initiated coverage on shares of Heartflow (NASDAQ:HTFL) in a research report sent to investors on Saturday morning,Weiss Ratings reports. The brokerage issued a sell (d+) rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Piper Sandler initiated coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an “overweight” rating and a $38.00 price objective for the company. Morgan Stanley started coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They issued an “equal weight” rating and a $35.00 price objective for the company. Zacks Research raised shares of Heartflow to a “hold” rating in a research report on Wednesday, September 3rd. Stifel Nicolaus assumed coverage on shares of Heartflow in a report on Tuesday, September 2nd. They issued a “buy” rating and a $35.00 price objective for the company. Finally, JPMorgan Chase & Co. initiated coverage on Heartflow in a research note on Tuesday, September 2nd. They issued an “overweight” rating and a $36.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $36.60.

Heartflow Stock Performance

Shares of HTFL stock opened at $34.04 on Friday. Heartflow has a fifty-two week low of $26.56 and a fifty-two week high of $41.22. The firm has a fifty day simple moving average of $34.41.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Friday, September 19th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The firm had revenue of $43.42 million for the quarter, compared to the consensus estimate of $43.20 million.

Institutional Investors Weigh In On Heartflow

Hedge funds and other institutional investors have recently modified their holdings of the business. Baillie Gifford & Co. purchased a new position in Heartflow during the 3rd quarter valued at about $101,182,000. Emerald Mutual Fund Advisers Trust acquired a new position in Heartflow during the third quarter worth $4,418,000. New York State Common Retirement Fund acquired a new stake in shares of Heartflow in the third quarter worth approximately $4,015,000. TrueMark Investments LLC purchased a new stake in Heartflow during the 3rd quarter valued at about $918,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Heartflow during the third quarter worth $234,000.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.